The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

The CDC began recommending Ixchiq last year for adults traveling to countries where chikungunya is common. The vaccine uses a ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

The FDA and CDC are investigating reports of serious adverse events, including deaths, in recipients of Ixchiq.

U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya vaccine while they investigate possible ...

The government of the United States has now advised its travelers who are of 60 years and above to not get a chikungunya ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

The use of Valneva’s chikungunya vaccine, known under the brand name Ixchiq, has been paused in elderly individuals after reports of serious adverse events (AEs) The US Food and Drug ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of Valneva’s chikungunya vaccine in older adults. The FDA and the ...

May 7 (Reuters) - The European Union's health regulator said on Wednesday it was reviewing French drugmaker Valneva's (VLS.PA), opens new tab chikungunya vaccine after reports of serious side ...

(Reuters) -The European Union's health regulator said on Wednesday it was reviewing French drugmaker Valneva's chikungunya vaccine after reports of serious side effects in older adults. The European ...